58 results
SC 14D9
PNT
POINT Biopharma Global Inc.
13 Oct 23
Tender offer solicitation
7:11am
basis, considering the risks and costs associated with its continued research and development of its product candidates and scaling up its … continued research and development of its product candidates and scaling up its manufacturing facility, and determined that the Offer, the Merger
SC TO-T
EX-99
PNT
POINT Biopharma Global Inc.
13 Oct 23
Third party tender offer statement
6:52am
of business and to supplement its research and development activities, Lilly regularly evaluates business development opportunities, including strategic … licenses ancillary to research, development, manufacture, clinical testing, sale, distribution and commercialization activities relating to products
SC TO-C
EX-99.1
PNT
POINT Biopharma Global Inc.
3 Oct 23
Information about tender offer
4:30pm
radiopharmaceutical manufacturing campus in Indianapolis, as well as a radiopharmaceutical research and development center in Toronto … combination or an asset acquisition, including any related acquired in-process research and development charges, according to Generally Accepted
SC14D9C
EX-2.1
PNT
POINT Biopharma Global Inc.
3 Oct 23
Written communication relating to third party tender offer
7:37am
is to ensure the safety, efficacy and quality of medicines or pharmaceuticals by regulating the research, development, manufacturing or distribution … Entity that provides for the provision of funding to the Company or any Company Subsidiary for research and development activities involving
SC14D9C
EX-99.4
ygi lhrgyhzpw370v
3 Oct 23
Written communication relating to third party tender offer
7:37am
8-K
EX-99.4
f56ew xt05sn45
3 Oct 23
Tender and Support Agreement
7:35am
8-K
EX-2.1
ep7jja0jo0eh1rcgycbu
3 Oct 23
Tender and Support Agreement
7:35am
8-K
EX-99.1
jnwd86 dw
14 Aug 23
POINT Biopharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights
7:21am
ARS
wuw75zns
1 May 23
Annual report to shareholders
1:52pm
8-K
EX-99.1
liaxj5fyz ooppa
14 Sep 22
POINT Biopharma Prices Public Offering of Common Stock
4:14pm
424B5
glsjyda2qsp4yoed
14 Sep 22
Prospectus supplement for primary offering
4:12pm
424B5
dzlj63
13 Sep 22
Prospectus supplement for primary offering
5:19pm
8-K
EX-99.1
uh20i
13 Sep 22
POINT Biopharma Announces Proposed Public Offering of Common Stock
4:12pm